



Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX Disclosure

Release of Shares from Voluntary Escrow

Melbourne (Australia) – 21 October 2021. Pursuant to ASX Listing Rule 3.10A Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') advises that ordinary shares voluntarily escrowed by China Grand Pharmaceutical and Healthcare Holdings Limited following the strategic commercial partnership and placement announced 2 November 2020, are to be released from escrow. These shares are already quoted on ASX.

**Number of ordinary shares
subject to voluntary escrow**

20,947,181

**Voluntary
escrow period**

12 months

**Escrow
release date**

5 November 2021

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on [Twitter](https://twitter.com/TelixPharma) (@TelixPharma) and [LinkedIn](https://www.linkedin.com/company/telix-pharmaceuticals).

Telix's lead investigational product, Illuccix[®] (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA,¹ and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA).² Telix is also progressing marketing authorisation applications for Illuccix[®] in the European Union³ and Canada.⁴ None of Telix's products have received a marketing authorisation in any jurisdiction.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.

¹ ASX disclosure 24/11/20.

² ASX disclosure 14/04/21.

³ ASX disclosure 1/05/20.

⁴ ASX disclosure 16/12/20.